Biochemical and Genetic Studies of UBR3, a Ubiquitin Ligase with a Function in Olfactory and Other Sensory Systems

Received for publication, March 5, 2007, and in revised form, April 24, 2007. Published, JBC Papers in Press, April 26, 2007. DOI 10.1074/jbc.M701894200

Takafumi Tasaki‡, Reinhard Sohr‡, Zanxian Xia§, Rainer Hellweg‡, Heide Hörttagl‡, Alexander Varshavsky*, and Yong Tae Kwon†

From the †Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, the ‡Institute of Pharmacology and Toxicology, Charité-Universität Medicine Berlin, Campus Mitte, Dorotheenstrasse 94, D-10117 Berlin, Germany, the ¶Division of Biology, California Institute of Technology, Pasadena, California 91125, and the ‡Department of Psychiatry and Psychotherapy, Charité-University Medicine Berlin, Campus Benjamin Franklin, Eschenallee 3, D-14050 Berlin, Germany

Our previous work identified E3 ubiquitin ligases, termed UBR1–UBR7, that contain the ~70-residue UBR box, a motif important for the targeting of N-end rule substrates. In this pathway, specific N-terminal residues of substrates are recognized as degradation signals by UBR box-containing E3s that include UBR1, UBR2, UBR4, and UBR5. The other E3s of this set, UBR3, UBR6, and UBR7, remained uncharacterized. Here we describe the cloning and analyses of mouse UBR3. The similarities of UBR3 to the UBR1 and UBR2 E3s of the N-end rule pathway include the RING and UBR domains. We show that HR6A and HR6B, the E2 enzymes that bind to UBR1 and UBR2, also interact with UBR3. However, in contrast to UBR1 and UBR2, UBR3 does not recognize N-end rule substrates. We also constructed UBR3-lacking mouse strains. In the 129SvImJ background, UBR3−/− mice died during embryogenesis, whereas the C57BL/6 background UBR3−/− mice exhibited neonatal lethality and suckling impairment that could be partially rescued by litter size reduction. The adult UBR3−/− mice had female-specific behavioral anosmia. Cells of the olfactory pathway were found to express β-galactosidase (LacZ) that marked the deletion/disruption UBR3−/− allele. The UBR3-specific LacZ expression was also prominent in cells of the touch, vision, hearing, and taste systems, suggesting a regulatory role of UBR3 in sensory pathways, including olfaction. By analogy with functions of the UBR domain in the N-end rule pathway, we propose that the UBR box of UBR3 may recognize small compounds that modulate the targeting, by this E3, of its currently unknown substrates.

A protein substrate of the ubiquitin (Ub)2-proteasome system, which controls the levels of many intracellular proteins, is conjugated to Ub through the action of E1, E2, and E3 enzymes (1–4). The selectivity of ubiquitylation is mediated largely by E3, which recognizes a substrate’s degradation signal (degron) (5–8). The E3 Ub ligases are an exceptionally large family, with more than 500 distinct E3s in a mammal (9, 10). The term “Ub ligase” denotes either an E2–E3 holoenzyme or its E3 component. A ubiquitylated protein bears a covalently linked poly-Ub chain and is targeted for processive degradation by the 26 S proteasome (11). Ub has other functions as well, including non-proteolytic ones (12, 13). An essential determinant of one class of degrons, called N-degrons, is a substrate’s destabilizing N-terminal residue. The set of destabilizing residues in a given cell type yields a rule, called the N-end rule, which regulates the in vivo half-life of a protein to the identity of its N-terminal residue (Fig. 1A) (4, 14–19). In eukaryotes, the N-degron consists of three determinants: a destabilizing N-terminal residue of a protein substrate, its internal Lys residue(s) (the site of formation of a poly-Ub chain), and a conformationally flexible region(s) in the vicinity of these determinants (5, 7, 15, 20, 21).

The N-end rule has a hierarchic structure in that some of the destabilizing N-terminal residues (Arg, Lys, His, Phe, Leu, Trp, Tyr, and Ile) are recognized directly by E3 Ub ligases of the N-end rule pathway, called N-recognition, whereas the other destabilizing N-terminal residues (Asn, Gln, Asp, Glu, and Cys) must be modified in vivo, enzymatically or otherwise, for their subsequent (indirect) recognition by these E3s (Fig. 1A) (18, 19, 22–25). The functions of the N-end rule pathway include its roles in the control of signaling by nitric oxide and G protein-coupled receptors (GPCRs), the regulation of peptide import, the fidelity of chromosome segregation, the apoptosis, meiosis, cardiovascular development, neurogenesis, and pancreatic functions, and leaf senescence in plants (16, 18, 24–32).

The N-end rule pathway of the yeast Saccharomyces cerevisiae is mediated by a single N-recognition, the Ub ligase UBR1 (33), whereas at least four N-recognition, including UBR1, medi-
ate this pathway in mammals (16, 17, 31, 34). Our recent study (17) identified a family of mammalian E3 Ub ligases that share a characteristic zinc finger-like ~70-residue domain termed the UBR box. The mouse genome encodes at least seven UBR box-containing proteins, termed UBR1–UBR7, which vary both in size (from 50 to 570 kDa) and in containing or lacking other E3-characteristic domains, such as HECT, RING, PHD, or F-box (Fig. 1B) (17). UBR1 and UBR2 of this set, the highly homologous (47% identical) 200-kDa E3s, are the known N-recognition sites of the mouse N-end rule pathway (16, 34).

In the S. cerevisiae RING-type UBR1 Ub ligase and also (by inference) in its mammalian homologs UBR1 and UBR2, the UBR box and nearby regions mediate the recognition of N-degrons (i.e. the binding of N-recognin to a primary destabilizing N-terminal residue (Arg, Lys, His, Phe, Leu, Trp, Tyr, or Ile) of a polypeptide) (16, 33). S. cerevisiae UBR1 recognizes type-1 (basic) destabilizing N-terminal residues Arg, Lys, and His through a binding site that resides at least in part in the UBR box. UBR1 recognizes type-2 (bulky hydrophobic) N-terminal residues Phe, Leu, Trp, and Tyr, and Ile through a nearby but genetically distinguishable domain that includes the UBR box and a proximal downstream region (see Refs. 17, 33, and 35 and references therein). S. cerevisiae UBR1 contains yet another (third) substrate-binding site. Its activity is allosterically controlled by occupancy states of the other two (type-1 and type-2) binding sites of UBR1. The third substrate-binding site targets the transcriptional repressor CUP9, through an internal degron near the C terminus of CUP9 (26, 33). Since mouse UBR1 and UBR2 are homologs of S. cerevisiae UBR1 (16, 36), one would expect these mammalian Ub ligases to also contain analogous (third) substrate-binding sites (Fig. 1A). Indeed, mouse UBR1 was shown to target c-FOS, a component of the AP-1 transcription factor, for ubiquitylation and subsequent degradation through a conditional (regulated by phosphorylation) degron near the N terminus of c-FOS (37). Several other UBR box-containing proteins, such as UBR4 (PUSHOVER/BIG) and UBR5 (EDD/hHYD), are also, operationally, N-recognins whose substrate specificities include the ability to recognize primary destabilizing N-terminal residues (16, 33).

We have previously characterized mammalian UBR1, UBR2, UBR4, and UBR5 as Ub ligases of the N-end rule pathway that recognize destabilizing N-terminal residues (16, 17, 34, 36). In the present study, we cloned and characterized mouse UBR3, a protein of unknown function that contains both the UBR box and the RING domain. Our findings show that UBR1, UBR2, and UBR3 are structurally related members of the RING-UBR subfamily of UBR-box E3s that interact (and function together) with the E2 enzymes HR6A and HR6B. We also constructed and characterized mouse strains lacking UBR3 and describe several lines of evidence suggesting that one function of UBR3 involves the regulation of sensory pathways, including olfaction.

**EXPERIMENTAL PROCEDURES**

**Cloning of the UBR3 cDNA**—A 412-bp cDNA fragment that encompassed a 3′-proximal region of the UBR3 ORF (see “Results”) was used as a probe to screen a AEXlox-based embryonic day 10 (E10) mouse embryo cDNA library (Novagen, Madison, WI), yielding a 2.5-kb UBR3 cDNA fragment. This fragment was employed as a probe in a second screen, using a λgt10-based mouse cDNA library from MEL-C19 cells (Clontech) and yielding in a 1-kb fragment. Two subsequent screenings yielded 2-kb and 1.5-kb fragments. To isolate the 5′ region of UBR3 cDNA, 5′-rapid amplification of cDNA ends PCR was performed with poly(A) + RNA from mouse liver or skeletal muscle. The resulting set of overlapping cDNA fragments were joined to produce full-length UBR3 cDNAs encoding two splicing-derived isoforms.

**Construction of UBR3−/− Mouse Strains**—The mouse UBR3 gene was isolated by screening a bacterial artificial chromosome (BAC) DNA library (Genome Systems, St. Louis, MO) from 129SvJ mouse embryonic stem (ES) cells by using a UBR3-specific cDNA probe (nucleotides 385–1,886). The exon/intron organization of the first ~30 kb of UBR3 was determined using exon-specific PCR primers to amplify genomic DNA fragments flanked by exons as previously described (34). The targeting vector was constructed using standard techniques, linearized with KpnI, and electroporated into CJ7 ES cells, followed by standard procedures for selection and identification of correctly targeted UBR3+/− ES cell colonies by using PCR and Southern hybridization (16, 22, 24, 34, 38). The resulting UBR3+/− ES cell clones (6 of 960 ES cell clones analyzed) were further selected for apparently normal karyotypes. Four independently produced UBR3+/− ES cell clones were injected into C57/BL6j blastocysts to generate chimeric mice. In two of these mice, the mutant (UBR3−) allele was transmitted to the germ line. Northern and Southern hybridizations and PCR-mediated genotyping were carried out as described (34).

**GST Pull-down Assays**—Glutathione S-transferase (GST) pull-down assays were carried out as described (16). N-terminally FLAG-tagged mouse UBR1, UBR2, and UBR3 and S. cerevisiae UBR1 (sc−UBR1) were expressed in S. cerevisiae SC295 (MATa, GAL4 GAL80 ura3-52, leu2-3,112 reg1-501 glpl pep3-4) from the pADH1 promoter in a high copy vector. X-SCC1-GST fusions (where X represents Met, Arg, or Leu) were produced using the IMPACT (intein-mediated purification with an affinity chitin-binding tag) system (New England Biolabs, Ipswich, MA) as previously described (16). N-terminal residues of the test proteins were verified by Edman sequencing of purified X-SCC1-GST fusions. GST fusions to mouse HR6A and HR6B (GST-HR6A and GST-HR6B) were expressed in Escherichia coli BL21(DE3) and purified as described (16). The purified X-SCC1-GST (2 μg) in 250 μl of the loading buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 10% glycerol, and 1% Triton X-100, pH 7.4) was incubated with 15 μl of glutathione-Sepharose beads (Amersham Biosciences) for 1 h at 4°C. The beads were washed once with the loading buffer and twice with the binding buffer (10% glycerol, 0.1% Nonidet P-40, 0.2 mM KCl, 1 mM dithiothreitol, and 50 mM HEPES, pH 7.5). The diluted yeast extracts (250 μl) containing E3s in binding buffer containing the protease inhibitor tablet (Roche Applied Science) were added into the washed beads. The bound proteins were eluted, fractionated by SDS-PAGE, and immunoblotted with anti-FLAG antibody. The 5% input lanes (see Fig. 2) refer to a directly loaded sample of the yeast extract that
corresponded to 5% of the extract amount used in GST pull-down assays.

X-Peptide Pull-down Assay—X-Peptides (X-Ile-Phe-Ser-Thr-Asp-Thr-Gly-Pro-Gly-Gly-Cys, where X represents Arg, Phe, Gly, Ser, Thr, Ala, Asp, or Met), where residues 2–9 were derived from residues 2–9 of Sindbis virus polymerase nsP4, were synthesized as described (17). S. cerevisiae extract expressing mouse UBR1, UBR2, or UBR3 was diluted by the lysis buffer (10% glycerol, 0.1% Nonidet P-40, 0.2 M KCl, 1 mM dithiothreitol, and 50 mM HEPES, pH 7.5) to 1.2 mg/ml of total protein and thereafter incubated with or without an added dipeptide for 15 min on ice to prevent proteolytic degradation of peptide substrates. A sample (0.3 ml) was then transferred to a new tube containing 5 μl (packed volume) of a carrier-linked 12-mer peptide, followed by gentle mixing, through rotation of the tube, for 1 h at 4 °C. The beads were pelleted by a brief centrifugation and then washed three times, for 2 min each, with the lysis buffer. The beads were then suspended in 20 μl of SDS-PAGE loading buffer and heated at 95 °C for 5 min, followed by a brief spin in a microcentrifuge, SDS-8% PAGE of the supernatant, and detection of UBR1, UBR2, or UBR3 by immunoblotting with anti-FLAG M2 antibody.

Antibody to Mouse UBR3—An affinity-purified polyclonal rabbit antibody to mouse UBR3 was produced using standard methods (34, 38, 39), using purified GST-UBR3-(182–598) fusion as an antigen. This antibody was employed to detect endogenous UBR3 through a combination of immunoprecipitation and immunoblotting (see Fig. 3D and “Results”).

LacZ Staining, Immunohistochemistry, and Northern Hybridization—LacZ staining (using 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and Northern hybridization (with a UBR3-specific 32P-labeled cDNA probe) were carried out as described (24). LacZ-stained embryos were postfixed, photographed, and sectioned after embedding in paraffin. Alternatively, the tissues were frozen in OCT medium after fixation, cryosectioned, and stained for LacZ on the slides. For immunohistochemistry, specific tissues were isolated, fixed in 4% formaldehyde, treated with 70% ethanol, dehydrated, and embedded in paraffin wax as described (16), followed by sectioning and staining with hematoxylin/eosin or an antibody. For Northern hybridization, a mouse adult tissue blot (Seegene, Seoul, Korea) containing total RNAs isolated from the brain, heart, lung, liver, spleen, kidney, stomach, small intestine, skeletal muscle, thymus, testis, uterine of nonpregnant female, and E17.5 placenta were hybridized with 32P-labeled cDNA fragments of mouse UBR3 or human β-actin. Northern analyses were also done with total RNAs from UBR3+/− brains and hearts versus their wild-type counterparts.

Assays for Neurotransmitters, Amino Acids, and Neurotrophins—Individual brains for each UBR3 genotype (+/+; +/−, and −/−) at the stages of E18 and postnatal day 1 (P1) were collected (6–8 brains of each genotype) to measure neurotransmitters and related compounds as described (40). The levels of monoamines (noradrenaline, dopamine, and serotonin) and their metabolites were determined using high performance liquid chromatography (HPLC) with electrochemical detection. Amino acids were measured using HPLC and fluorescence spectroscopy (41). The levels of nerve growth factor and brain-derived neurotrophic factor in the brains were determined by enzyme-linked immunoassay (42).

Odor-based Behavioral Tests—Odorant discrimination tests were performed largely as described (43) with minor modifications. UBR3+/− mice (7–17 weeks old) with littermate controls (+/+ and UBR3+/−) were individually housed in filter-topped cages 2 days before the test. On the third day, the test mouse was relocated to a designated area away from other mice and was left there for 30 min to allow accommodation to the environment. Pretraining sessions and odorant tests with mice are described under “Results.” Odorant solutions (50 μM) were made freshly in deionized water (for isomyl acetate and ethyl vanillin) or mineral oil (for geraniol and citral). One experimenter performed the entire set of odorant tests without knowing the genotypes of mice being tested.

RESULTS

Cloning of Mouse cDNAs Encoding UBR3—Data base search using UBR1 and UBR2 sequences as probes brought forth a 388-bp cDNA fragment (GenBank™ accession number W83893) encoding a partial open reading frame that exhibits a weak but significant homology to C-terminal regions of UBR1 and UBR2. By employing cDNA library screening and 5′-rapid amplification of cDNA ends PCR, we cloned the ~8- to kb full-length mouse cDNA, yielding nine overlapping cDNA fragments that represented two isoforms of a ~213-kDa protein named UBR3. The predicted mouse UBR3 cDNA isoforms, encoding the proteins of 1,889 and 1,893 residues, respectively, contained distinct exon/intron boundaries, indicating alternative RNA splicing (data not shown). Reverse transcription-PCR analysis detected comparable mRNA levels of UBR3 isoforms in the liver and skeletal muscle (data not shown). Northern hybridization indicated that the two UBR3 mRNAs, of ~8 and ~6.5 kb, were expressed in a broad range of tissues, with higher levels in the brain and skeletal muscle (Fig. 1D). UBR3 exhibited a low but significant sequence similarity (22% identity) to the 200-kDa mouse UBR1 and UBR2, which are 47% identical (Fig. 1C).

Significantly, UBR3 contained all of the domains (the UBR box, the WxRNG domain, the RING-H2 finger, and the autoinhibitory domain) that have been identified in UBR1 and UBR2 (Fig. 1C). Thus, operationally, UBR1, UBR2, and UBR3 comprise a distinct RING-UBR subfamily of UBR Ub ligases. UBR3 Binds to E2 Ub-conjugating Enzymes HR6A and HR6B—We have previously shown that either of the E2 Ub-conjugating enzymes HR6A and HR6B supports the UBR1-mediated degradation of N-end rule substrates (34) and that mouse UBR1 and UBR2 bind to HR6B (16). Mouse HR6A and HR6B are 95% identical and are functional counterparts of the S. cerevisiae E2 enzyme RAD6/Ubc2 whose multiple functions include the N-end rule pathway, where RAD6 is a part of the UBR1-RAD6 Ub ligase (44, 45). To determine whether mouse UBR3 binds to HR6A and HR6B, we expressed the N-terminally FLAG-tagged mouse UBR3 and UBR1 in S. cerevisiae. Purified GST-HR6A or GST-HR6B fusion proteins were bound to glutathione-conjugated beads, and GST pull-down assays were carried out with yeast extracts expressing UBR1 or UBR3. Both UBR3 and UBR1 bound to GST-HR6A and GST-HR6B but not to S. cerevisiae-derived GST-RAD6 (negative control) (Fig. 2, A and B).
Together with earlier findings with mouse UBR1 and UBR2 (16, 34), these results (Fig. 2, A and B) suggest that HR6A and HR6B are E2s that form the holoenzyme Ub ligases with, in particular, E3s of the RING-UBR subfamily. The latter consists, at present, of UBR1, UBR2, and UBR3.

**UBR3 Does Not Bind to Known N-end Rule Substrates of UBR1 and UBR2**—The X-peptide pull-down assay that we developed previously (17) was used to determine whether UBR3 can recognize destabilizing N-terminal residues that are known to be bound by UBR1 and UBR2 (Fig. 2C). An *S. cerevisiae* extract expressing UBR1, UBR2, or UBR3 was incubated with an immobilized 12-mer X-peptide (X-Ile-Phe-Ser-Thr-Asp-Thr-Gly-Pro-Gly-Gly-Cys, where X represents Arg (type-1 primary destabilizing residue), Phe (type-2 primary destabilizing residue), Asp (secondary destabilizing residue), Met, Gly, Ser, Thr, or Ala), followed by a pull-down assay and anti-FLAG immunoblotting. Consistent with earlier results (17), UBR1 and UBR2 bound to X-peptides bearing either type-1 or type-2 destabilizing N-terminal residues but not to other N-terminal residues (Fig. 2D). In contrast, UBR3 did not bind to any of the tested X-peptides (Fig. 2D). To verify this finding, we employed a different binding assay, with X-SCC1-GST fusions (where X represents Arg (type-1 destabilizing residue), Leu (type-2 destabilizing residue), or Met (stabilizing residue)). The SCC1 moiety of these fusions is a 33-kDa separase-produced C-terminal fragment of the *S. cerevisiae* cohesin subunit SCC1 that bears N-terminal Arg and is rapidly degraded by the N-end rule pathway (16, 27). As expected, sc-fUBR1 bound to Arg-SCC1 but not to Met-SCC1. However, UBR3 did not interact with any of these substrates (Fig. 2E), consistent with both the present X-peptide data (Fig. 2D) and the analogous earlier assays with mouse tissue extracts that identified UBR1, UBR2, UBR4, and UBR5 but...
not UBR3 (17) (data not shown). We conclude that UBR3 does not bind to known substrates of the N-end rule pathway.

The pattern of E2–E3 interactions in the mammalian RING-UBR subfamily is analogous to the disposition in S. cerevisiae, where RAD6, a homolog of HR6A and HR6B, functions as a common E2 for the yeast RING-UBR subfamily, which consists of sc-UBR1 (the sole E3 of the S. cerevisiae N-end rule pathway) (15) and sc-UBR2, which does not bind to N-end rule substrates (46). It remains to be determined whether mammalian UBR3 is functionally analogous to sc-UBR2.

UBR3 Knock-out in Mice Results in Strain-dependent Phenotypes—To address the physiological functions of UBR3, we constructed UBR3<sup>−/−</sup> mouse strains. BAC clones encoding mouse UBR3 were isolated from a strain 129-derived SvJ BAC library. Data base analyses indicated that UBR3 encompasses ~130 kb of mouse chromosome 2 and ~260 kb of human chromosome 2. Using restriction mapping and sequencing, we determined the structure of a ~30-kb genomic fragment spanning the 5' upstream region and exons 1–5 of mouse UBR3 in the UBR3 targeting vector, a region spanning exon 1 (encoding most of the UBR box) and its flanking intron were replaced with <i>nlsLacZ-neo</i> that encodes <i>E. coli lacZ</i> (β-galactosidase) fused to a nuclear localization signal, followed by the floxed (flanked by the <i>loxP</i> sites) PGK/Neo cassette. In the resulting UBR3<sup>−/−</sup> deletion/disruption allele, the <i>nlsLacZ</i> mRNA is produced from the endogenous UBR3 promoter (Fig. 3A). Mouse chimeras carrying the desired UBR3<sup>−/−</sup> (<i>UBR3<sup>nlsLacZ</sup></i>) allele were produced using standard ES cell-based methods (16, 22, 24, 34). These mice were crossed with either C57BL/6J (denoted as B6) or 129SvImJ (denoted as 129S) wild-type females, yielding F1 offspring in either mixed (B6/129S) or inbred (129S) backgrounds. The deletion/disruption allele was confirmed by Southern analysis (Fig. 3B), and the absence of UBR3 mRNA in UBR3<sup>−/−</sup> mice was confirmed by Northern analysis (Fig. 3C). The purified GST-UBR3-(182–598) fusion protein was used as an antigen to produce a polyclonal, affinity-purified anti-UBR3 antibody (see “Experimental Procedures”). Anti-UBR3 immunoprecipitation-immunoblotting with mouse tissue extracts confirmed the absence of UBR3 in UBR3<sup>−/−</sup> mice (Fig. 3D).

UBR3<sup>−/−</sup> mice in the mixed (B6/129S) background were born at a frequency slightly lower than the expected Mendelian frequency (Table 1). They were fertile and apparently normal, indicating that UBR3 is not essential for viability and fertility in this genetic background. In contrast, no UBR3<sup>−/−</sup> mice in the inbred (129S) background were retrieved from 207 adult mice and 78 embryos (from E3.5 to E16.5) that were produced from heterozygous intercrosses, suggesting that UBR3 knock-out in this background causes lethality in early embryogenesis. We therefore wished to analyze the phenotypes of UBR3<sup>−/−</sup> mice in a C57BL/6J (B6)-enriched genetic background. B6-enriched UBR3<sup>−/−</sup> mice were produced through backcrosses to wild-type B6 females for 8–12 generations (N8–N12) over a period of ~3 years. Unexpectedly, these (B6-enriched) UBR3<sup>−/−</sup> mice exhibited neonatal lethality.

**Impaired Suckling and Neonatal Death of B6 Background UBR3<sup>−/−</sup> Mice—**B6 background-enriched UBR3<sup>−/−</sup> embryos were apparently normal in growth and other developmental features. At birth, their body weight (1.30 ± 0.04 g; n = 15) was ~10% lower compared with +/+ pups (1.46 ± 0.05 g; n = 10). Despite the growth retardation, UBR3<sup>−/−</sup> neonates appeared normal in body color, breathing behavior, touch response,
righting, and vocalization, indicating that they were not severely impaired in cardiovascular and respiratory systems, motor coordination, and related functions. Notably, however, ~60% of \( UBIR3^{-/-} \) neonatal pups exhibited impaired milk sucking, as determined by the presence and amounts of milk in the stomachs (Fig. 4). Although \( UBIR3^{-/-} \) pups were present in the nest together with littersmates and moved their mouths apparently normally, the affected \( UBIR3^{-/-} \) pups became weak, exhibited dehydration, and usually died within 2 days after birth. Dead \( UBIR3^{-/-} \) pups did not exhibit significant anatomical abnormalities in the palate, mouth, and esophagus in comparison with wild-type pups or surviving \( UBIR3^{+/+} \) pups. Both \( UBIR3^{+/+} \) and \( UBIR3^{-/-} \) mothers appeared to nurture their pups normally, showing standard crouching, retrieving, and stimulating responses toward all newborns. In summary, the absence of \( UBIR3 \) in neonatal mice, most of the apparently normal (with milk in their stomachs) pups at P1 were removed from three litters (\( n = 29 \) pups), so that the litters (each of them reduced to three or four pups) contained 1–4 suckling-impaired pups per litter. Of the seven suckling-impaired pups in three reduced size litters, four pups (three \( UBIR3^{-/-} \) and one \( UBIR3^{+/+} \)) survived until adulthood, whereas one \( UBIR3^{-/-} \) pup was found dead, and two were cannibalized. The surviving \( UBIR3^{-/-} \) pups grew to adulthood without significant growth retardation and were fertile, with normal mating behavior. These results suggest that litter size reduction, and thereby a reduced competition for lactating nipples, could partially rescue neonatal \( UBIR3^{-/-} \) pups and that B6 background \( UBIR3^{-/-} \) neonates die of starvation rather than developmental failure.

Expression of LacZ/\( UBIR3 \) in Sensory Cells for Olfactory and Tactile Sensation—Given the phenotype of impaired sucking in B6-enriched \( UBIR3^{-/-} \) pups, we employed the nls-lacZ reporter to examine the expression patterns of \( UBIR3 \) (Fig. 3A), with an emphasis on sensory tissues. LacZ expression patterns in various organs did not differ significantly between \( UBIR3^{+/+} \) and \( UBIR3^{-/-} \) mice, indicating that \( UBIR3 \) knock-out did not cause major developmental abnormalities. Odorants and pheromones (i.e. the odorants of conspecific origin) are detected primarily by the main olfactory epithelium (MOE) and the vomeronasal organ (VNO), respectively (51, 52). The binding of olfactants to G protein-coupled olfactory receptors (53) on the surfaces of olfactory sensory neurons in MOE initiates signaling cascades that involve specific receptor-coupled G proteins and their transient activation by receptor-bound odorants. This activation transduces and amplifies the initial signal through production of cyclic AMP and phosphoinositide derivatives, activating specific ion channels in an olfactory neuron. The resulting changes in membrane potential give rise to action potentials that propagate from olfactory neurons to a glomerular region of the olfactory bulb (OB), where synaptic connections with mitral cells convey the resulting (processed) signals to olfactory cortex (OC) (52, 54). In contrast, pheromones are detected by specific GPCRs in VNO. The axons of vomeronasal sensory neurons project to mitral cells in glomeruli of the accessory olfactory bulb, relaying the (processed) signals to other regions of the brain (54). LacZ-marked \( UBIR3 \) was found to be prominently expressed in cells of the olfactory pathway, including the olfactory cell layer of MOE, a mitral neuron cell layer of OB, and a pyramidal cell layer of the piriform cortex of OC (Fig. 5, A–E). The expression of \( UBIR3 \) was also strong in the vomeronasal sensory epithelium of VNO and the mitral cells of the accessory olfactory bulb (Fig. 5, F and G). In neonates, tactile stimuli to whiskers and sinus hairs of lips activate primary somatosensory afferent neurons (trigeminal nerve) that innervate vibrissal follicle-sinus complexes (49). \( UBIR3 \) was prominently expressed in tactile tissues, including the dorsal root ganglion, trigeminal ganglion, and follicle-sinus complexes (Fig. 6, A–F). In follicle-sinus complexes, the \( UBIR3 \)-specific LacZ staining was prominent in cells between hair follicle and sinus and also in the region of the rete ridge collar (Fig. 6, E and F). These results indicated that \( UBIR3 \) is prominently expressed in sensory cells involved in olfactory and tactile sensations, both of which are important for normal sucking in neonatal mice.
behavior. **UBR3** was found to be prominently expressed in taste buds of the fungiform, circumvallate, and foliate papillae, where ~50–100 taste sensory cells are organized into anatomically distinct groups (Fig. 6, K and L). Auditory information (the intensity and frequencies of sound) is received and relayed by mechanosensory hair cells in the organ of Corti of the inner ear. Voltage-gated channels in the stereocilia of hair cells open and close in response to physical movements of hairs (specialized cilia), giving rise to action potentials (57). Hair cells form synapses with cells of the innervated spiral (cochlear) ganglion, thereby relaying their signals to specific regions of the brain. **UBR3** was prominently expressed, in spatially confined patterns, in the spiral ganglion and the organ of Corti of the cochlea in the inner ear (Fig. 6, G–I). In the organ of Corti, **UBR3** was expressed in the inner hair cells and outer hair cells, both of which are mechanosensory cells. **UBR3**-specific LacZ staining was also present in the sensory epithelium of macula and vestibular ganglion of the balancing system (Fig. 6, G and J). Photons of light are detected by photoreceptor cells in the retina and are transduced into action potentials by light-activated cells. These signals, transmitted and processed by bipolar neurons and the rest of the retinal neural network, are conveyed via the optic nerve to specific regions of the brain (58, 59). Similarly to the findings with other sensory organs (Figs. 5 and 6, A–L), the expression of LacZ/UBR3 was conspicuous in the ganglion cell layer and developing photoreceptor cells of the retina (Fig. 6, M and N). In summary, the **UBR3**-specific LacZ marker was specifically and prominently expressed in sensory cells that underlie the major five senses (smell, touch, vision, hearing, and taste), suggesting that UBR3-dependent ubiquitylation regulates the reception or processing of sensory signals (Figs. 5 and 6).

Because **UBR3** is also expressed outside the nervous system (Fig. 1D), its remarkably specific expression patterns in sensory tissues (Figs. 5 and 6) reflect only a subset of **UBR3** functions, most of which remain to be discovered. In this initial study of
UBR3, which includes its cloning, biochemical characterization, and the construction of UBR3−/− mice, we focused on the expression of UBR3 in sensory organs primarily because of the serendipitous discovery of suckling impairment in UBR3−/− neonates (Fig. 4), a defect that is likely to stem, at least in part, from abnormal olfaction.

**UBR3−/− Mice Are Impaired in Olfaction-based Behavior—** Histological examination of sections of B6-enriched UBR3−/− heads at E18 or P1 did not detect anatomical abnormalities in OE, OB, and periformal cortex, where UBR3 is prominently expressed (see above). Immunohistochemical staining of sections from +/+ and UBR3−/− P2 pups also did not reveal significant alteration in the expression and distribution of olfactory neuronal markers, such as the olfactory marker protein (OMP) and type III adenyl cyclase (Fig. 5, H–K). To determine the survival and growth of neurons, we measured the levels of neurotrophins in UBR3−/− animals at E18 and P1 together with littermate controls. UBR3 knock-out did not affect significantly the levels of nerve growth factor (0.16 ± 0.02 pg/mg of tissue in +/+ (n = 6), 0.19 ± 0.02 in +/+ (n = 10), and 0.15 ± 0.02 in −/− (n = 7)) and brain-derived neurotrophic factor (10.1 ± 1.3 pg/mg in +/+ (n = 6), 10.5 ± 1.3 in +/+ (n = 10), and 10.5 ± 0.8 in −/− (n = 7)) in the brains of P1 pups, as were E18 embryos (data not shown). Microarray analyses of 22,000 mouse genes (Affymetrix GeneChips) coupled with selective quantitative reverse transcription-PCR with mRNAs isolated from +/+ and UBR3−/− P1 brains did not detect genes whose expression was altered more than 2-fold in the mutant.3

The ability of olfactory neurons to convey signals to OB is underlain by the biosynthesis, transport, and release of specific neurotransmitters, such as catecholamines (60). We determined the effect of UBR3 loss on the levels of neurotransmitters and related substances, including dopamine, noradrenaline, homovanillic acid (a major catabolite of dopamine), γ-aminobutyric acid, glutamate, serotonin, 5-hydroxyindoleacetic acid, taurine, and tyrosine. In the whole brains at E18 or P1, the absence of UBR3 did not affect the levels of these compounds. In contrast, the OB of P1 UBR3−/− neonates contained a significantly reduced level of noradrenaline but not of other tested compounds, compared with control neonates. Dopamine, a precursor of noradrenaline, was also affected in P1 UBR3−/− pups to a lesser extent (Table 2). Since earlier studies implicated catecholamines in olfaction and other senses (61–63), the above results (Table 2) suggest that UBR3 is required, in particular, for normal regulation of catecholamines.

The lethality associated with impaired suckling in UBR3−/− neonates (Fig. 4) and the expression of UBR3 in sensory cells of the olfactory pathway (Fig. 5) suggest that one physiological function of UBR3 is in olfaction. To begin addressing this possibility, we employed an odor-based behavioral test, with 7–17-week-old UBR3−/− mice that naturally survived or were rescued by litter size reduction. In a pretest, mice were exposed three times (2-min exposures with 1-min intervals) to a water-dipped cotton swab, and the number of times a mouse sniffed or approached to explore the swab was recorded at each trial. The control (+/+ and UBR3−/−) and the UBR3−/− mice (both males and females) proactively sniffed or explored water-dipped swabs in pretests in which swab was a novel object (Fig. 7A). The sniffing counts of all three genotypes decreased in subsequent trials in which a water-dipped swab was no longer a novel object (Fig. 7A). These results suggest that UBR3−/− mice are not significantly impaired in the exploratory activity and are normally habituated to the swab. One minute after the pretest, the same procedure was repeated but with a swab laced with an odorant, such as isoamyl acetate (a pearlike odor), citral (a lemon-like odor), ethyl vanillin (a vanilla-like odor), and geraniol (a rose-like odor). As expected, the control (+/+ and UBR3−/−) mice actively responded to the swab laced with these odors (Fig. 7B). In contrast, UBR3−/− mice were found to exhibit the behavioral anosmia toward tested odors. Remarkably, this defect was confined to UBR3−/− females (Fig. 7B). Thus, UBR3 appears to regulate olfactory behavior and does so, in adult mice, in a gender-specific manner. Together with the expression patterns of UBR3 (Figs. 1D, 5, and 6), these initial functional insights, the beginning of broader explorations, hint at wide ranging functions of UBR3, both inside and outside the nervous system.

### Table 2

| Noradrenaline | Dopamine | Homovanillic acid | γ-Aminobutyric acid | Glutamate | Serotonin | 5-Hydroxyindoleacetic acid | Taurine | Tyrosine |
|---------------|----------|-------------------|--------------------|----------|-----------|---------------------------|--------|---------|
| pg/mg tissue | pg/mg tissue | pg/mg tissue | pmol/mg tissue | pg/mg tissue | pg/mg tissue | pmol/mg tissue | pg/mg tissue | pmol/mg tissue |
| E18 braina |            |                  |                  |          |           |                            |        |         |
| ++ | 95.2 ± 9.7 | 46.4 ± 7.6 | 33.1 ± 6.0 | 1.57 ± 0.06 | 5.08 ± 0.12 | 53.9 ± 7.0 | 217 ± 25 | 21.6 ± 0.4 | 3.98 ± 0.29 |
| +/− | 85.1 ± 4.2 | 40.5 ± 4.4 | 26.7 ± 2.3 | 1.61 ± 0.04 | 5.05 ± 0.13 | 52.7 ± 6.6 | 209 ± 6 | 21.1 ± 0.5 | 3.18 ± 0.19 |
| −/− | 89.0 ± 6.7 | 43.1 ± 4.9 | 30.4 ± 2.9 | 1.58 ± 0.06 | 5.14 ± 0.23 | 61.7 ± 6.8 | 183 ± 10 | 21.7 ± 0.7 | 3.68 ± 0.20 |
| P1 brainb |            |                  |                  |          |           |                            |        |         |
| ++ | 164 ± 9.7 | 99.0 ± 3.5 | 43.7 ± 6.0 | 1.46 ± 0.09 | 3.46 ± 0.13 | 203 ± 33 | 944 ± 95 | 27.9 ± 0.9 | 3.62 ± 0.52 |
| +/− | 185 ± 11 | 108 ± 4.3 | 41.0 ± 6.4 | 1.56 ± 0.10 | 3.77 ± 0.28 | 245 ± 33 | 947 ± 89 | 29.8 ± 1.6 | 3.68 ± 0.33 |
| −/− | 162 ± 3.2 | 93.1 ± 2.9 | 36.3 ± 4.7 | 1.31 ± 0.04 | 3.22 ± 0.12 | 223 ± 46 | 1114 ± 99 | 26.7 ± 0.7 | 3.10 ± 0.26 |
| P1 OBc |            |                  |                  |          |           |                            |        |         |
| ++ | 100 ± 16.9 | 54.9 ± 11.4 | 55.9 ± 12.3 | 1.25 ± 0.24 | 5.14 ± 0.50 | 61.0 ± 7.2 | 267 ± 30 | 38.3 ± 2.4 | 3.55 ± 0.45 |
| +/− | 80.5 ± 19.4 | 56.8 ± 5.9 | 51.8 ± 6.2 | 1.17 ± 0.10 | 4.43 ± 0.37 | 66.9 ± 4.0 | 286 ± 25 | 31.9 ± 2.5 | 3.25 ± 0.41 |
| −/− | 41.4 ± 14.3 | 32.4 ± 8.6 | 50.2 ± 12.3 | 1.00 ± 0.11 | 3.78 ± 0.38 | 61.3 ± 9.0 | 321 ± 40 | 30.4 ± 2.7 | 2.62 ± 0.46 |

**Note:**

a *p < 0.05 versus P1 OB +/+; one-way analysis of variance.

3 T. Tasaki and Y. T. Kwon, unpublished data.
The fact that only a subset of UBR-box proteins can bind to destabilizing N-terminal residues (16, 17) (this study), indicates that the sequence motif termed the UBR box (Fig. 1C) functions as a scaffold for specific three-dimensional structures of distinct binding specificities. At present, the only known class of specific ligands that bind to UBR boxes is that of N-degrons, specifically their destabilizing N-terminal residues, in either protein size or peptide size ligands. However, given our results with UBR3 (Fig. 2), other, non-N-end rule physiological ligands of the UBR domain (e.g. those that bind to UBR of UBR3) are expected to exist as well. One function of the UBR boxes in the known N-recognins (Fig. 1) is nutritional sensing. Specifically, *S. cerevisiae* UBR1 binds, in part through its UBR box, to short peptides bearing destabilizing N-terminal residues. This binding allosterically activates a third substrate-binding site of UBR1 that targets an internal (non-N-degron) degradation signal of UCP9, a transcriptional repressor of peptide import. This design of yeast UBR1 yields a positive feedback circuit that can detect intracellular peptides and up-regulate their import (16, 26, 33). By analogy, a UBR box of UBR3 may bind to (currently unknown) small metabolites. Similarly to the binding of dipeptidyl-tide-2 to the type-1/2 binding sites of UBR1 (see Introduction), the binding of a small effector to UBR3 may activate its other substrate-binding site (presumed to exist by analogy to UBR1/UBR2), thereby altering the rate of ubiquitylation of a relevant regulatory protein(s). If so, one interesting possibility is that a small compound ligand and/or a protein target(s) of UBR3 may be the same in otherwise diverse physiological processes that involve UBR3 in different sensory tissues.

The phenotypes of *UBR3*−/− mouse strains that were characterized in this work are strongly dependent on genetic background. Specifically, *UBR3*−/− mice of the inbred (129S) background died as early embryos, for reasons that remain to be determined. In contrast, *UBR3*−/− mice of the mixed (B6/129S) background, although they were born at lower than expected frequencies (Table 1), were fertile, of normal size, and apparently normal otherwise as well. Remarkably, our systematic, long term (over ~3 years) enrichment of *UBR3*−/− mice in the B6 genetic background yielded a reproducible and conspicuous phenotype, a strongly increased lethality of newborn *UBR3*−/− pups, largely if not entirely because of impaired suckling (Fig. 4 and Table 1). The dependence of viability and other phenotypes of *UBR3*−/− mice on their genetic background (Table 1) indicate the presence of genes whose alleles functionally interact with *UBR3*.

The finding that UBR3 is prominently expressed in neurons and/or other cells that mediate sensory pathways, including the five major senses (Figs. 5 and 6), suggested a role of UBR3 in the corresponding physiological processes. The vision, smell, and taste are mediated primarily by specific GPCR signaling pathways. For example, the rhodopsin, a photon-stimulated photoreceptor in the eye’s retina, initiates a cGMP-dependent signal transduction cascade that leads to the action potential (58). The MOE, the VNO, and taste buds also express specific GPCRs that recognize, respectively, various odorants, pheromones, and a set of substances that elicit sensations of taste, such as sweet, bitter, and umami (56). The second messengers for these sensory GPCR signaling pathways are primarily cyclic AMP (olfactory neurons and taste sensory cells (for sweet and
UBR3 Ubiquitin Ligase and N-End Rule Pathway

Acknowledgments—We are grateful to Jai Wha Seo for genotyping and maintaining mouse strains, to S. Pease (Caltech) for assistance with ES cell work, to B. Kennedy (Caltech) and the staff of the animal facility at the University of Pittsburgh for the care and maintenance of mice, and to A. Arnswald and A. Bunge for excellent technical assistance.

REFERENCES

1. Fang, S., and Weissman, A. M. (2004) Cell Mol. Life Sci. 61, 1546–1561
2. Hochstrasser, M. (2006) Cell 124, 27–34
3. Petroski, M. D., and Deshaies, R. J. (2005) Nat. Rev. Mol. Cell. Biol. 6, 9–20
4. Varshavsky, A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 647–654
5. Bachmair, A., and Varshavsky, A. (1989) Cell 56, 1019–1032
6. Gardner, R. G., and Hampton, R. Y. (1999) EMBO J. 18, 5994–6004
7. Suzuki, T., and Varshavsky, A. (1999) EMBO J. 18, 6017–6026
8. Sheng, J., Kumagai, A., Dunphy, W. G., and Varshavsky, A. (2002) EMBO J. 21, 6061–6071
9. Cardozo, T., and Pagano, M. (2004) Nat. Rev. Mol. Cell. Biol. 5, 739–751
10. Arldt, H. C., and Robinson, P. A. (2005) Essays Biochem. 41, 15–30
11. Baumeister, W., Walz, J., Zühl, F., and Seemüller, E. (1998) Cell 92, 367–380
12. Finley, D., Bartel, B., and Varshavsky, A. (1989) Nature 338, 394–401
13. Schnell, J. D., and Hicke, L. (2003) J. Biol. Chem. 278, 35857–35860
14. Bachmair, A., Finley, D., and Varshavsky, A. (1986) Science 234, 179–186
15. Varshavsky, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12142–12149
16. Kwon, Y. T., Xia, Z. X., An, J. Y., Tasaki, T., Davydov, I. V., Seo, J. W., Xie, Y., and Varshavsky, A. (2003) Mol. Cell. Biol. 23, 8255–8271
17. Tasaki, T., Mulder, L. C. F., Iwamatsu, A., Lee, M. J., Davydov, I. V., Varshavsky, A., Muesing, M., and Kwon, Y. T. (2005) Mol. Cell. Biol. 25, 7120–7136
18. Hu, R.-G., Sheng, J., Xin, Q., Xu, Z., Takahashi, T. T., and Varshavsky, A. (2005) Nature 437, 981–986
19. Hu, R.-G., Brower, C. S., Wang, H., Davydov, I. V., Sheng, J., Zhou, J., Kwon, Y. T., and Varshavsky, A. (2006) J. Biol. Chem. 281, 32559–32573
20. Johnson, E. S., Gonda, D. K., and Varshavsky, A. (1990) Nature 346, 287–291
21. Prakash, S., Tian, L., Ratliff, K. S., Lehotzky, R. E., and Matouschek, A. (2004) Nat. Struct. Mol. Biol. 11, 830–837
22. Kwon, Y. T., Balogh, S. A., Davydov, I. V., Kashina, A. S., Yoon, J. K., Xie, Y., Gaur, A., Hyde, L., Denenberg, V. H., and Varshavsky, A. (2000) Mol. Cell. Biol. 20, 4135–4148
23. Kwon, Y. T., Kashina, A. S., and Varshavsky, A. (1999) Mol. Cell. Biol. 19, 182–193
24. Kwon, Y. T., Kashina, A. S., Davydov, I. V., Hu, R.-G., An, J. Y., Seo, J. W., Du, F., and Varshavsky, A. (2002) Science 297, 96–99
25. Lee, M. J., Tasaki, T., Moroi, K., Lee, M. J., Varshavsky, A., and Kwon, Y. T. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 15303–15305
26. Turner, G. C., Du, F., and Varshavsky, A. (2000) Nature 405, 579–583
27. Rao, H., Uhlfmann, F., Nasmuth, K., and Varshavsky, A. (2001) Nature 410, 955–960
28. Ditzel, M., Wilson, R., Tenev, T., Zachariou, A., Paul, A., Deas, E., and Meier, P. (2003) Nat. Cell. Biol. 5, 467–473
29. Varshavsky, A. (2003) Nat. Cell. Biol. 5, 373–376
30. Yoshida, S., Ito, M., Gallis, J., Nishida, I., and Watanabe, A. (2002) Plant J. 29, 129–137
31. An, J. Y., Seo, J. W., Tasaki, T., Lee, M. J., Varshavsky, A., and Kwon, Y. T. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 6212–6217
32. Zenker, M., Mayerle, J., Lerch, M. M., Tagariello, A., Zerres, K., Durie, P. R., Beier, M., Häuslamps, G., Guzman, C., Behnder, H., Beemer, F. A., Hamel, B., Vanliefinghen, P., Gershoni-Baruch, R., Vieira, M. W., Dumic, M., Ausladen, R., Gil-da-Silva-Lopes, V. L., Steinlicht, S., Rauh, R., Shahav, S. A., Thiel, C., Winterpacht, A., Kwon, Y. T., Varshavsky, A., and Reis, A. (2005) Nat. Genet. 37, 1345–1350
33. Du, F., Navarro-Garcia, F., Xia, Z., Tasaki, T., and Varshavsky, A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 14110–14115
34. Kwon, Y. T., Xia, Z., Davydov, I. V., Lecker, S. H., and Varshavsky, A. (2001) Mol. Cell. Biol. 21, 8007–8021
35. Erbse, A., Schmidt, R., Bornemann, T., Schneider-Mergener, J., Mogk, A., Zahn, R., Dougan, D. A., and Bukau, B. (2005) Nature 439, 753–756
36. Kwon, Y. T., Reiss, Y., Fried, V. A., Hershko, A., Yoon, J. K., Gonda, D. K., Sangan, P., Copeland, N. G., Jenkins, N. A., and Varshavsky, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7898–7903
37. Sasaki, T., Kojima, H., Kishimoto, R., Ikeda, A., Kunimoto, H., and Nakajima, K. (2006) Mol. Cell 24, 63–75
UBR3 Ubiquitin Ligase and N-End Rule Pathway

38. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A., Seidman, J. G., and Struhl, K. (eds). (2002) Current Protocols in Molecular Biology, Wiley-Interscience, New York
39. Harlow, E., and Lane, D. (1999) Using Antibodies: a laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
40. Chourbaji, S., Hellweg, R., Brandis, D., Zörner, B., Zacher, C., Lang, U. E., Henn, F. A., Hörtner, H., and Gass, P. (2004) Brain Res. Mol. Brain Res. 121, 28–36
41. Piepponen, T. P., and Skujins, A. (2001) J. Chromatogr. B. Biomed. Sci. Appl. 757, 277–283
42. Hellweg, R., Baethge, C., Hartung, H. D., Bruckner, M. K., and Arendt, T. (1996) Neuroreport 7, 777–780
43. Trinh, K., and Storm, D. R. (2003) Nat. Neurosci. 6, 519–525
44. Dohmen, R. J., Madura, K., Bartel, B., and Varshavsky, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7351–7355
45. Dover, J. J., Schneider, J., Boateng, M. A., Wood, A., Dean, K., Johnston, M., and Shilatifard, A. (2002) J. Biol. Chem. 277, 28368–28371
46. Wang, L., Mao, X., Ju, D., and Xie, Y. (2004) J. Biol. Chem. 279, 55218–55223
47. Belluscio, L., Gold, G. H., Nemes, A., and Axel, R. (1998) Neuron 20, 69–81
48. Wong, S. T., Trinh, K., Hacker, B., Chan, G. C., Lowe, G., Gaggar, A., Xia, Z., Gold, G. H., and Storm, D. R. (2000) Neuron 27, 487–497
49. Kutsuwada, T., Sakimura, K., Manabe, T., Takayama, C., Katakura, N., Kushiya, E., Natsume, R., Watanabe, M., Inoue, Y., Yagi, T., Aizawa, S., Arakawa, M., Takahashi, T., Nakamura, Y., Mori, H., and Mishina, M. (1996) Neuron 16, 333–344
50. Brunet, L. J., Gold, G. H., and Ngai, J. (1996) Neuron 17, 681–693
51. Mombaerts, P. (2004) Nat. Rev. Neurosci. 5, 263–278
52. Ache, B. A., and Young, J. M. (2005) Neuron 48, 417–430
53. Buck, L., and Axel, R. (1991) Cell 65, 175–187
54. Firestein, S. (2001) Nature 413, 211–218
55. Lindemann, B. (2001) Nature 413, 219–225
56. Scott, K. (2005) Neuron 48, 455–464
57. Lin, S. Y., and Corey, D. P. (2005) Curr. Opin. Neurobiol. 15, 350–357
58. Maeda, T., Imanishi, Y., and Palczewski, K. (2003) Prog. Retin. Eye Res. 22, 417–434
59. Burns, M. E., and Arshavsky, V. Y. (2005) Neuron 48, 387–401
60. Murphy, G. J., Darcy, D. P., and Isaacson, J. S. (2005) Nat. Neurosci. 8, 354–364
61. Bear, M. F., and Singer, W. (1986) Nature 320, 172–176
62. Guan, X., Blank, J., and Dluzen, D. (1993) Brain Res. 622, 51–57
63. Smeets, W. J., and Gonzalez, A. (2000) Brain Res. Rev. 33, 308–379
64. Dalton, P., Doolittle, N., and Breslin, P. A. (2002) Nat. Neurosci. 5, 199–200